AR081828A1 - Compuestos de biguanida y su uso para el tratamiento del cancer - Google Patents

Compuestos de biguanida y su uso para el tratamiento del cancer

Info

Publication number
AR081828A1
AR081828A1 ARP110101794A ARP110101794A AR081828A1 AR 081828 A1 AR081828 A1 AR 081828A1 AR P110101794 A ARP110101794 A AR P110101794A AR P110101794 A ARP110101794 A AR P110101794A AR 081828 A1 AR081828 A1 AR 081828A1
Authority
AR
Argentina
Prior art keywords
denotes
coor11
replaced
hal
atoms
Prior art date
Application number
ARP110101794A
Other languages
English (en)
Inventor
Tijana Tomic
Robert Ballotti
Vincent Aroles
Stephane Rocchi
Original Assignee
Inserm Transfert
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inserm Transfert, Merck Patent Gmbh filed Critical Inserm Transfert
Publication of AR081828A1 publication Critical patent/AR081828A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Reivindicación 1: Compuesto de la fórmula (1), en donde R1, R2 cada uno, de modo independiente entre sí, denota H, A, Alk, (CH2)nAr, (CH2)nCyc o (CH2)nHet; R1 y R2 juntos también denotan una cadena de alquileno que tiene 2, 3, 4, 5 ó 6 átomos de C, en donde un grupo CH2 puede estar reemplazado por O, S, SO, SO2, NH, NR8, NCOR8 o NCOOR8, y en donde la cadena de alquileno no está sustituida o está mono-, di- o trisustituida con Hal, A, OR11, N(R11)2, NO2, CN, fenilo, =O, CON(R11)2, NR11COA, NR11CON(R11)2, NR11SO2A, COR11, SO2N(R11)2, S(O)mA, -[C(R11)2]n-COOR11 y/u -O[C(R11)2]o-COOR11; A denota alquilo C1-10 no ramificado o ramificado, en donde uno, dos o tres grupos CH y/o CH2 pueden estar reemplazados por O, S, SO, SO2, NH, NR8 y/o con grupos -CH=CH- y/o, además, 1 - 5 átomos de H pueden estar reemplazados por F, Cl, Br y/o R7; Cyc es cicloalquilo C3-7; Alk denota alquenilo C2-6 o alquinilo C2-6; R7 denota COOR9, CONR9R10, NR9R10, NHCOR9, NHCOOR9 u OR9; R8 denota cicloalquilo C3-7, cicloalquilalquileno C4-10, Alk o alquilo C1-6 no ramificado o ramificado; R9, R10 cada uno, de modo independiente entre sí, denota H o alquilo C1-6, en donde 1 - 3 grupos CH2 pueden estar reemplazados por O, S, SO, SO2, NH, NMe o NEt y/o, además, 1 - 5 átomos de H pueden estar reemplazados por F y/o Cl; Ar denota fenilo, naftilo o bifenilo, cada uno de los cuales no está sustituido o está mono-, di- o trisustituido con Hal, A, OR11, N(R11)2, NO2, CN, fenilo, CON(R11)2, NR11COA, NR11CON(R11)2, NR11SO2A, COR11, SO2N(R11)2, S(O)mA, -[C(R11)2]n-COOR11 y/u -O[C(R11)2]o-COOR11; Het denota un heterociclo saturado, insaturado o aromático mono- o bicíclico que tiene 1 a 4 átomos de N, O y/o S, que puede estar mono-, di- o trisustituido con Hal, A, OR11, N(R11)2, NO2, CN, COOR11, CON(R11)2, NR11COA, NR11SO2A, COR11, SO2NR11, S(O)mA, =S, =NR11 y/u =O (oxígeno del carbonilo); R11 denota H o A; Hal denota F, Cl, Br o I; m denota 0, 1 ó 2; n denota 0, 1, 2, 3 ó 4; o denota 1, 2 ó 3; excluyendo los compuestos de la fórmula (1) en donde: a) R1 = H, R2 = H; b) R1 = H, R2 = fenetilo; y sus sales, solvatos, tautómeros y estereoisómeros farmacéuticamente aceptables, incluyendo sus mezclas en todas las proporciones, para usar en la prevención y/o el tratamiento de cáncer.
ARP110101794A 2010-05-26 2011-05-26 Compuestos de biguanida y su uso para el tratamiento del cancer AR081828A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10005432 2010-05-26

Publications (1)

Publication Number Publication Date
AR081828A1 true AR081828A1 (es) 2012-10-24

Family

ID=44534228

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101794A AR081828A1 (es) 2010-05-26 2011-05-26 Compuestos de biguanida y su uso para el tratamiento del cancer

Country Status (4)

Country Link
US (1) US20130059916A1 (es)
EP (1) EP2575792A1 (es)
AR (1) AR081828A1 (es)
WO (1) WO2011147528A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913736A1 (en) 2012-06-11 2013-12-19 The Regents Of The University Of California Compounds and methods of treating cancer
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHODS OF EVALUATION RISK OF DEVELOPMENT OF PML
WO2015026215A1 (ko) * 2013-08-23 2015-02-26 가톨릭대학교 산학협력단 바이구아나이드 유도체 화합물을 유효성분으로 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약제학적 조성물
KR101642587B1 (ko) 2013-08-23 2016-07-25 가톨릭대학교 산학협력단 바이구아나이드 유도체 화합물을 유효성분으로 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약제학적 조성물
SG10202005315SA (en) * 2014-08-19 2020-07-29 Nat Univ Corporation Okayama Univ Agent for treating and/or preventing diseases associated with immune abnormalities by combining biguanide antidiabetic drug with immunosuppressive factor blocking agent or costimulatory receptor agonist
CN104230760B (zh) * 2014-09-02 2016-07-06 浙江工业大学 N-芳基取代的双胍氢溴酸盐类化合物及制备方法和应用
KR102216701B1 (ko) 2014-11-20 2021-02-18 이뮤노메트테라퓨틱스 인코포레이티드 바이구아나이드 화합물 및 이의 용도
JP7358403B2 (ja) * 2018-06-05 2023-10-10 アンスティテュ・クリー ビグアニジルラジカルを含む新規化合物及びその使用
US11065188B2 (en) * 2019-05-29 2021-07-20 Av Laboratories Llc Applications and formulations of optimized, modified human embryonic fertility culture media with biguanides and/or functional equivalents
CN113354561B (zh) * 2021-04-17 2023-03-28 中山大学 双胍衍生物及其应用与制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2322860A1 (fr) 1975-09-05 1977-04-01 Aron Sarl Procede de preparation de chlorhydrate de dimethylbiguanide
ES2218543T3 (es) 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CN1431999A (zh) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 具有血管损伤活性的吲哚衍生物
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
FR2858232B1 (fr) * 2003-07-29 2006-03-03 Pierre Potier Utilisation d'un derive de biguanide pour proteger la peau des radiations uvb
US20080194019A1 (en) 2003-09-09 2008-08-14 Beth Israel Deaconess Medical Center, Inc. Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
CN1846694B (zh) * 2005-04-12 2012-02-01 中国医学科学院血液学研究所 取代芳香基双胍类化合物及含它们的药物组合物在制备抗恶性肿瘤药物方面的应用
CA2666036C (en) * 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
KR101083300B1 (ko) * 2008-10-13 2011-11-14 한국화학연구원 Ｎ1-벤조［1,3］다이옥솔-5-일메틸-ｎ2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물

Also Published As

Publication number Publication date
US20130059916A1 (en) 2013-03-07
WO2011147528A1 (en) 2011-12-01
EP2575792A1 (en) 2013-04-10

Similar Documents

Publication Publication Date Title
AR081828A1 (es) Compuestos de biguanida y su uso para el tratamiento del cancer
AR096235A1 (es) Arilquinazolinas
AR089944A1 (es) Derivados de tetrahidro-quinazolinona
AR090602A1 (es) AMIDAS CICLICAS Y HETEROCICLOS COMO INHIBIDORES DE MetAP-2
AR067506A1 (es) Derivados de quinazolinamida
AR074418A1 (es) Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores
AR084507A1 (es) Derivados de indazoliltriazol
AR054047A1 (es) Derivados de fenilquinazolina
AR092211A1 (es) Derivados de hidropirrolopirrol
AR070649A1 (es) Derivados de 1,3- dihidro -isoindol
AR052482A1 (es) Derivados de triazol como inhibidores de hsp90
AR051135A1 (es) Fenilpirazoles
AR082726A1 (es) Derivados de triazolopirazina
AR096684A1 (es) Compuestos para tratar atrofia muscular espinal
AR061735A1 (es) Derivados de indazol, composiciones farmaceuticas y uso de los mismos
AR093725A1 (es) Quinazolincarboxamida azetidinas
AR073055A1 (es) Derivados biciclicos de triazol
AR082728A1 (es) Imidazolonilquinolinas utiles para tratar el cancer, composiciones farmaceuticas que las contienen, proceso de sintesis, intermediarios de dicha sintesis y procedimiento para prepararlos
AR061009A1 (es) 1,2-difenil-pirazoles i i como inhibidores de hsp90
AR072192A1 (es) Derivados de tiazolil-piperidina
AR107738A1 (es) Amidas de ácido n-(5-halógen-1,3,4-oxadiazol-2-il)arilcarboxílico y su uso como herbicidas
AR068658A1 (es) Derivados de tiazol
AR082722A1 (es) Derivados de pirimidina
AR082727A1 (es) Derivados de furopiridina, procesos de preparacion y composiciones farmaceuticas que los contienen
AR072860A1 (es) Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure